乳腺空芯针活检诊断为小叶上皮内瘤变后升级为恶性肿瘤的风险:系统评价与Meta分析
该系统评价与Meta分析检索1998至2020年文献,纳入65篇全文、其中16项符合全部质量标准的原始研究,采用随机效应模型合并经影像一致的小叶上皮内瘤变经空芯针活检诊断后的升级风险。合并升级为任何恶性肿瘤的风险为全部小叶上皮内瘤变3.1%(95%CI 1.8%-5.2%)、非典型小叶增生2.5%(95%CI 1.6%-3.9%)、经典型小叶原位癌5.8%(95%CI 2.9%-11.3%)。作者结论认为小叶上皮内瘤变活检后升级风险低,影像随访可能可作为手术处理的替代选择,尤其对非典型小叶增生。
要点
- 影像一致、经典型小叶上皮内瘤变经空芯针活检诊断后,合并升级为任何恶性肿瘤的风险为3.1%(95%CI 1.8%-5.2%)。
- 非典型小叶增生升级为任何恶性肿瘤2.5%(95%CI 1.6%-3.9%),经典型小叶原位癌5.8%(95%CI 2.9%-11.3%)。
- 全部65篇文献中升级为任何恶性肿瘤的风险范围为0%至45%。
核心结论
- 乳腺活检发现的小叶上皮内瘤变升级为恶性肿瘤的风险低。
- 影像随访可能可替代手术处理小叶上皮内瘤变,尤其对非典型小叶增生。
研究设计与样本
- 研究类型为系统评价与Meta分析,检索PubMed和Embase 1998至2020年发表的原始文章。
- 纳入65篇全文文章;其中16项研究符合全部质量标准的纳入Meta分析。
- 质量评价标准为排除变异型小叶原位癌、排除影像不一致病灶、≥70%病灶有结局报告。
- 采用随机效应模型估计合并风险。
诊断标准与关键数值
- 全部小叶上皮内瘤变升级为任何恶性肿瘤(浸润性癌或导管原位癌)的合并风险3.1%(95%CI 1.8%-5.2%),升级为浸润性恶性肿瘤的合并风险1.3%(95%CI 0.7%-2.4%)。
- 非典型小叶增生升级为任何恶性肿瘤的合并风险2.5%(95%CI 1.6%-3.9%),升级为浸润性恶性肿瘤的合并风险0.4%(95%CI 0.0%-4.2%)。
- 经典型小叶原位癌升级为任何恶性肿瘤的合并风险5.8%(95%CI 2.9%-11.3%),升级为浸润性恶性肿瘤的合并风险3.5%(95%CI 2.0%-5.9%)。
临床应用与阅片要点
- 系统评价纳入的65篇文献中,升级为任何恶性肿瘤的风险范围为0%至45%。
- 作者认为影像随访可能可替代手术处理小叶上皮内瘤变,尤其对非典型小叶增生。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: Lobular neoplasia (LN) detected on breast core needle biopsy is frequently managed with surgical excision because of concern for undersampled malignancy. The authors performed a systematic review and meta-analysis to estimate the risk for upgrade to malignancy in the setting of imaging-concordant classic LN diagnosed on core biopsy.
METHODS: PubMed and Embase were searched for original articles published from 1998 to 2020 that reported rates of upgrade to malignancy for classic LN, including atypical lobular hyperplasia (ALH) and classic lobular carcinoma in situ (LCIS). Two reviewers extracted study data and assessed the following quality criteria: exclusion of variant LCIS, exclusion of imaging-discordant lesions, and outcome reporting for ≥70% of lesions. For studies meeting all criteria, pooled risks for upgrade to any malignancy (invasive carcinoma or ductal carcinoma in situ) and invasive malignancy for all LN, ALH, and LCIS were estimated using random-effects models.
RESULTS: For 65 full-text articles included in the review, the risk for upgrade to any malignancy ranged from 0% to 45%. Among the 16 studies that met all quality criteria for the meta-analysis, pooled risks for upgrade to any malignancy were 3.1% (95% confidence interval [CI], 1.8%-5.2%) for all LN, 2.5% (95% CI, 1.6%-3.9%) for ALH, and 5.8% (95% CI, 2.9%-11.3%) for LCIS. Risks for upgrade to invasive malignancy were 1.3% (95% CI, 0.7%-2.4%) for all LN, 0.4% (95% CI, 0.0%-4.2%) for ALH, and 3.5% (95% CI, 2.0%-5.9%) for LCIS.
CONCLUSIONS: The risk for upgrade to malignancy for LN found on breast biopsy is low. Imaging surveillance can likely be offered as an alternative to surgical management for LN, particularly for ALH.
引用
- Shehata MN, Rahbar H, Flanagan MR, et al. Risk for Upgrade to Malignancy After Breast Core Needle Biopsy Diagnosis of Lobular Neoplasia: A Systematic Review and Meta-Analysis. J Am Coll Radiol. 2020. PMID: 32861602. doi:10.1016/j.jacr.2020.07.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。